An immune checkpoint score system for prognostic evaluation and adjuvant chemotherapy selection in gastric cancer

Jia-Bin Wang, Ping Li, Xiao-Long Liu, Qiao-Ling Zheng, Yu-Bin Ma, Ya-Jun Zhao, Jian-Wei Xie, Jian-Xian Lin, Jun Lu, Qi-Yue Chen, Long-Long Cao, Mi Lin, Li-Chao Liu, Ning-Zi Lian, Ying-Hong Yang (), Chang-Ming Huang () and Chao-Hui Zheng ()
Additional contact information
Jia-Bin Wang: Fujian Medical University Union Hospital
Ping Li: Fujian Medical University Union Hospital
Xiao-Long Liu: The United Innovation of Mengchao Hepatobiliary Technology Key Laboratory of Fujian Province
Qiao-Ling Zheng: Fujian Medical University Union Hospital
Yu-Bin Ma: The Affiliated Hospital of Qinghai University
Ya-Jun Zhao: The First Affiliated Hospital of USTC, University of Science and Technology of China
Jian-Wei Xie: Fujian Medical University Union Hospital
Jian-Xian Lin: Fujian Medical University Union Hospital
Jun Lu: Fujian Medical University Union Hospital
Qi-Yue Chen: Fujian Medical University Union Hospital
Long-Long Cao: Fujian Medical University Union Hospital
Mi Lin: Fujian Medical University Union Hospital
Li-Chao Liu: Fujian Medical University Union Hospital
Ning-Zi Lian: Fujian Medical University Union Hospital
Ying-Hong Yang: Fujian Medical University Union Hospital
Chang-Ming Huang: Fujian Medical University Union Hospital
Chao-Hui Zheng: Fujian Medical University Union Hospital

Nature Communications, 2020, vol. 11, issue 1, 1-14

Abstract: Abstract Immunosuppressive molecules are extremely valuable prognostic biomarkers across different cancer types. However, the diversity of different immunosuppressive molecules makes it very difficult to accurately predict clinical outcomes based only on a single immunosuppressive molecule. Here, we establish a comprehensive immune scoring system (ISSGC) based on 6 immunosuppressive ligands (NECTIN2, CEACAM1, HMGB1, SIGLEC6, CD44, and CD155) using the LASSO method to improve prognostic accuracy and provide an additional selection strategy for adjuvant chemotherapy of gastric cancer (GC). The results show that ISSGC is an independent prognostic factor and a supplement of TNM stage for GC patients, and it can improve their prognosis prediction accuracy; in addition, it can distinguish GC patients with better prognosis from those with high prognostic nutritional index score; furthermore, ISSGC can also be used as a tool to select GC patients who would benefit from adjuvant chemotherapy independent of their TNM stages, MSI status and EBV status.

Date: 2020
References: Add references at CitEc
Citations: View citations in EconPapers (1)

Downloads: (external link)
https://www.nature.com/articles/s41467-020-20260-7 Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:11:y:2020:i:1:d:10.1038_s41467-020-20260-7

Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/

DOI: 10.1038/s41467-020-20260-7

Access Statistics for this article

Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie

More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().